SAN DIEGO --(BUSINESS WIRE)--Aug. 3, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed David Karlander as Senior Vice President of Commercial Operations. With more than 25 years of industry experience, Karlander will lead all
Reimbursement decision expands access to testing that provides critical information used to guide targeted treatment options for patients with breast cancer Company provides updates on other initiatives including CNSide™, its proprietary test for neuro-oncology, and COVID-19 testing volume, which
Expanded Board to build on company’s recent successes in oncology diagnostics and COVID-19 testing SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to
SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will participate at the following investment conferences: Brookline Capital Markets Newport
Expands company’s patent portfolio in pursuit of worldwide intellectual property protection for proprietary technology that detects biomarkers in tissue, blood, and cerebrospinal fluid SAN DIEGO --(BUSINESS WIRE)--Jul. 6, 2021-- Biocept, Inc . (NASDAQ: BIOC), a leading provider of molecular
SAN DIEGO --(BUSINESS WIRE)--Jun. 28, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will be added to the Russell Microcap Index after the U.S. market opens today, June 28, 2021 .
SAN DIEGO --(BUSINESS WIRE)--Jun. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing services to Quest patients for its Target Selector™
SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020 .
Integrated solution incorporates testing protocols and real-time test results to help ensure safer, healthier campuses, healthcare facilities and other venues SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
SAN DIEGO --(BUSINESS WIRE)--Jun. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m.
